| 172.36 0.04 (0.02%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kidney disease (ADPKD). The pipeline further includes omaveloxolone, currently in Phase II development for Friedreich's ataxia. Reata is also advancing Phase 2 studies for various other chronic kidney diseases, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, and focal segmental glomerulosclerosis, among others. Beyond these, the company's earlier-stage development includes RTA 901, aimed at neurological disorders, and RTA 1701, which holds potential for treating a spectrum of autoimmune, inflammatory, and fibrotic conditions. The company has established strategic partnerships, including an agreement with Kyowa Kirin Co., Ltd. for the development and commercialization of bardoxolone across various renal, cardiovascular, diabetes, and metabolic indications within a broad territory spanning Japan, China, Hong Kong, Macao, South Korea, Taiwan, and several Southeast Asian nations (Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia). Additionally, Reata collaborates with AbbVie Inc. to jointly research, develop, and commercialize second- and later-generation Nrf2 activators for all indications excluding renal, cardiovascular, and metabolic applications. Originally incorporated in 2002 as Reata Discovery, Inc., the company officially became Reata Pharmaceuticals, Inc. in May 2005. It is headquartered in Plano, Texas.
Thu, 24 Apr 2025
RETA Stock Price, News & Analysis - Stock Titan
Wed, 01 Nov 2023
Former Reata Pharmaceuticals CFO steps into new role with California biotech company - The Business Journals
Tue, 26 Sep 2023
Biogen Completes Acquisition of Reata Pharmaceuticals - Biogen
Mon, 25 Sep 2023
Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio? - Yahoo Finance
Wed, 13 Sep 2023
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future - Yahoo Finance
Fri, 28 Jul 2023
Biogen to Acquire Reata Pharmaceuticals - Biogen
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|